Ferrante Karen Jean 4

What Happened Karen Jean Ferrante, a director of Cogent Biosciences, received a grant of 686 derivative securities (stock options) on April 1, 2026. The options were issued at $0.00 cash cost to the reporting person (a non-cash award under the company's director compensation plan). The Form 4 was filed on April 3, 2026.

Key Details

• Transaction date: 2026-04-01; Filing date: 2026-04-03 (filed within the 2-business-day Form 4 window).
• Transaction type: Award/Grant of derivative securities (code A).
• Quantity: 686 options; reported acquisition price: $0.00 (no cash paid).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote: Ferrante elected to take director compensation in the form of options instead of cash. The number of options was determined by dividing the cash compensation amount for the quarter by the Black‑Scholes value of a single option on the grant date.

Context This is a routine director compensation award rather than an open‑market purchase or sale. Derivative awards paid in lieu of cash are common for non-employee directors and do not by themselves indicate a buy/sell signal; the filing does not show any immediate sale or cashless exercise of the options.